018680.KQ Seoul Pharma Co. Ltd

Healthcare Oil, Gas & Consumable Fuels KOSDAQ
1,691 KRW
Close of Oct 30, 2026
1,612 3,310
Market cap
KRW 19.7B
P/E
11.9x
P/B
0.49x
ROE
-2.5%
Dividend yield
-
Fundamental score
1.6/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 018680.KQ undervalued?

Graham number
Price1,691
Graham value3,328
Discount49.2%

018680.KQ trades 49.2% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Seoul Pharma Co. Ltd fundamental analysis

8 of 21 checks passed

ROE 0/2

Low return on equity (-2.5%), below 10%.

ROA 0/1

Return on assets (-1.5%) is below the industry median (1.4%).

Profit Consistency 1/2

Profitable for 4 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-55.6%) is below the industry median (1.8%).

Revenue Growth 1/2

Revenue grew 1.4% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 2/2

Loss-making but free cash flow is positive.

PE vs Market 0/1

PE (11.9x) is above the market median (11.3x).

PE vs Industry 0/1

PE (11.9x) is above the industry median (11.4x).

PBV 1/1

Price to book (0.5x) is below the industry median (0.9x).

Graham Number 1/1

The price is below the Graham number (PE x PB = 5.8, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Seoul Pharma Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Seoul Pharma Co. Ltd

Seoul Pharma Co., Ltd manufactures and sells pharmaceutical products in South Korea and internationally. The company offers orally disintegrating film products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency; and CH.V, as well a…

Full company profile